RT Journal Article
SR Electronic
T1 Threshold-based Identification of Persistent Infarction after Successful Endovascular Treatment: Re-evaluating the “Core”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.09.20048744
DO 10.1101/2020.04.09.20048744
A1 Raphael Meier
A1 Paula Lux
A1 Richard McKinley
A1 Simon Jung
A1 Urs Fischer
A1 Jan Gralla
A1 Roland Wiest
A1 Johannes Kaesmacher
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.09.20048744.abstract
AB Objectives The objectives of this study included the volumetric analysis of persistent infarction and lesion reversal in Diffusion-Weighted Imaging (DWI), as well as the assessment of accuracy of ADC thresholds to identify regions of persistent infarction in patients with acute ischemic stroke after successful endovascular treatment (EVT).Materials and Methods A retrospective analysis of patients with M1 or proximal M2 occlusions, treated between 01/2012 and 07/2017, who underwent successful EVT (≥TICI 2b) and both pre- and post-interventional Magnetic Resonance Imaging (MRI), led to the inclusion of N=90 patients. Administration of recombinant tissue plasminogen activator (rTPA) for intra-venous thrombolysis was performed ahead of intervention in 45 cases (N=45/90, 50%). The majority of patients (N=78/90, 86.7%) were treated with second-generation thrombectomy devices with or without intra-arterial urokinase. DWI at admission and 24-hour follow-up DWI data were co-registered. Acute ischemic changes at baseline DWI, 24-hour DWI lesion, and the affected gray/white matter regions were manually annotated. Persistent infarction was defined as acute ischemic changes on baseline DWI, which were sustained on 24-hour follow-up DWI. Based on the manual annotations, persistent infarction and DWI reversal were quantified in a voxel-wise analysis. Thresholds for the identification of persistent infarction using baseline ADC images were estimated by maximizing Youden’s J statistic (ROC-analysis).Results Median age of the patients was 71.9 years (IQR 60.4–79.7 years), 55.6% were female, and NIHSS at admission was 11 (IQR 6–14). The median DWI lesion volume at baseline was 9.9 mL (IQR 3–23.6 mL) and the median DWI lesion volume around 24 hours was 12.1 mL (IQR 3.6–23.7 mL). Reversal of acute ischemic changes occurred frequently (49.8%, IQR 31.7%–65.4%; percentage of initial DWI lesion volume per subject). Sizeable DWI reversal (i.e. >10 mL and >10%) was observed in 26.7% (N=24/90) of the cases. Relative DWI reversal was significantly higher in white matter (58.6%, IQR 35.3–81.5%) than in gray matter (39.2%, IQR 24.9–56.6%; p<0.001). The volume of persistent infarction and DWI reversal were both significantly correlated with the DWI lesion volume at baseline (R=0.873–0.945, p<0.001), however, no correlations with time to reperfusion were found (relative volumes: R=-/+0.058, p=0.607). ROC analyses of ADC thresholds yielded optimal values which differed significantly for gray and white matter (p=0.003), and were lower than previously reported thresholds while having significantly improved accuracy (p≤0.015). No correlations between the estimated ADC thresholds and different covariates were found (time from imaging to reperfusion, time from baseline to follow-up imaging, volume of acute ischemic changes).Conclusions DWI reversal occurs frequently in successfully reperfused patients treated with modern EVT. Identification of persistent infarction using ADC thresholds in baseline DWI remains challenging with notable differences for gray and white matter.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; U.F. has received research grants from Medtronic (SWIFT DIRECT and BEYOND SWIFT) and does consultancy for Medtronic, Stryker and CSL Behring outside the submitted work. J.G. has received research grants from Medtronic (SWIFT DIRECT and BEYOND SWIFT) and does consultancy for Medtronic outside the submitted work.Funding StatementThis study was supported by funding received from Swiss National Science Foundation (grant no. 320030L_170060 STRAY-CATS) and the Swiss Heart Foundation (grant no. FF17033 & FF18059).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw patient-level data that support the findings of this study are available from the corresponding author on reasonable request and after clearance by the local ethics committee.